Newsroom
  • Press Releases
  • Presentations
Investors
  • Overview
  • Warrant Exercise Inquiries
  • Restricted Stock Inquiries
  • Notice to Stockholders
  • News / Events
  • Company Information
  • Financial Information
  • Stock Data
  • SEC Filings
  • Corporate Governance
Clinical Trial Enrollment
  • Triple-Negative Breast Cancer
  • COVID-19 Mild to Moderate
  • COVID-19 Severe or Critical
  • COVID-19 Long-Haulers
Contact

CytoDyn Inc.

  • Home
  • About CytoDyn
    • Meet CytoDyn
  • Our Science
  • Pipeline
    • Overview
    • HIV
    • Cancer
    • GVHD
    • COVID-19
  • Expanded Access
  • Our Team
    • Management Team
    • Board of Directors
  • Careers
    • Now Hiring
  • Scientific Board of Advisors
  • Newsroom
  • Investors
  • Clinical Trial Enrollment
  • Contact
Latest News

FOR THE LATEST DEVELOPING NEWS Click Here

Hospitals Enrolling COVID-19 Severe-to-Critical

Investment Community Webcast on Wednesday, April 7

Antibody-based strategies in HIV therapy

Leronlimab in International Journal of Infectious Diseases

Manuscript Accepted by Infectious Diseases Society of America

Into the Looking Glass: Post-Viral Syndrome Post COVID-19

Local drug trial provides hope for COVID ‘long-haulers’

Leronlimab’s Mechanism of Action in COVID-19 Published

Leronlimab role in COVID-19

Experimental Drugs Aim to Treat Long-Haul Covid Patients

Leronlimab and Long-Haulers

Research on Critically Ill COVID-19 Patients Published in Journal of Translational Autoimmunity

Case Study of Critically Ill Person with COVID-19 on ECMO Successfully Treated with Leronlimab Published in Journal of Translational Autoimmunity

Dr. Seethamraju’s Presentation at Special isirv-AVG Virtual Conference

Press Releases

Newsroom

Newsroom

  • Press Releases
  • Presentations

CytoDyn Announces Phase IIB Clinical Trial Agreement with Dr. Jeffrey Jacobson, Drexel University College of Medicine

Nov 16, 2012 1:41pm EST

CytoDyn to Present Findings on its Feline Immunodeficiency Virus (FIV) Therapeutic Antibody Program

Oct 05, 2012 8:45am EDT

CytoDyn Retains Gibraltar Associates for Corporate and Investor Communications

Oct 03, 2012 10:02am EDT

CytoDyn Inc. Names Dr. Nader Pourhassan New CEO; Announces New Chief Scientific Officer

Sep 11, 2012 5:52pm EDT

CytoDyn Announces Management Update Conference Call on Thursday, August 23

Aug 21, 2012 4:56pm EDT

CytoDyn Announces Entry into Agreement with Progenics Pharmaceuticals, Inc. to Acquire PRO 140

Jul 30, 2012 2:01pm EDT
RSS
  • Prev
    • 1...
    • 26
    • 27
    • 28
    • 29
    • 30
    • 31
    • 32
    • 33
    • 34
    • 35
    © 2021 CytoDyn Inc. All Rights Reserved.
    • Twitter
    • Facebookj
    Privacy Policy Disclaimer Sitemap